Matrilin-1 is an inhibitor of neovascularization

Journal of Biological Chemistry

Volumn 289, Issue 20, 2014, Pages 14301-14309

  Foradori, Matthew J ^a,b   Chen, Qian ^c   Fernandez, Cecilia A ^a,b   Harper, Jay ^a,b   Li, Xin ^c   Tsang, Paul C W ^d   Langer, Robert ^e   Moses, Marsha A ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BROWN UNIVERSITY   (United States)

^d UNIVERSITY OF NEW HAMPSHIRE   (United States)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMATOGRAPHY; CLONING; ENDOTHELIAL CELLS; MAMMALS; MASS SPECTROMETRY; RECOMBINANT PROTEINS;

ANGIOGENESIS INHIBITORS; ANTI-ANGIOGENIC ACTIVITY; CAPILLARY ENDOTHELIAL CELLS; CATION EXCHANGE CHROMATOGRAPHY; CHICK CHORIOALLANTOIC MEMBRANE; INHIBITORY ACTIVITY; NEO-VASCULARIZATION; TANDEM MASS SPECTROMETRY;

PURIFICATION;

CD31 ANTIGEN; MATRILIN; MATRILIN 1; MATRIX METALLOPROTEINASE; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN RECEPTOR; ANGIOGENESIS INHIBITOR;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; FRACTURE HEALING; GROWTH INHIBITION; IN VITRO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PEPTIDE MAPPING; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; AMINO ACID SEQUENCE; ANGIOGENESIS; ANIMAL; BOVINAE; CELL MOTION; CHEMISTRY; CHICKEN; CYTOLOGY; DRUG EFFECTS; FRACTURE; GENE INACTIVATION; GENETICS; HUMAN; MALE; METABOLISM; MOLECULAR GENETICS; PATHOPHYSIOLOGY; TIBIA; WOUND HEALING;

AMINO ACID SEQUENCE; ANGIOGENESIS INHIBITORS; ANIMALS; CATTLE; CELL MOVEMENT; CELL PROLIFERATION; CHICKENS; ENDOTHELIAL CELLS; FRACTURES, BONE; GENE KNOCKOUT TECHNIQUES; HUMANS; MALE; MATRILIN PROTEINS; MICE; MOLECULAR SEQUENCE DATA; NEOVASCULARIZATION, PHYSIOLOGIC; TIBIA; WOUND HEALING;

EID: 84900992805     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.529982     Document Type: Article

References (56)

1. Liang, J. H., and Wong, K. P. (2000) The characterization of angiogenesis inhibitor from shark cartilage. Adv. Exp. Med. Biol. 476, 209-223
2. Kim, D. H., Kim, Y. T., Cho, J. J., Bae, J. H., Hur, S. B., Hwang, I., and Choi, T. J. (2002) Stable integration and functional expression of flounder growth hormone gene in transformed microalga, Chlorella ellipsoidea. Mar. Biotechnol. 4, 63-73
3. Hiraki, Y., and Shukunami, C. (2005) Angiogenesis inhibitors localized in hypovascular mesenchymal tissues: chondromodulin-I and tenomodulin. Connect. Tissue Res. 46, 3-11
4. Moses, M. A., Sudhalter, J., and Langer, R. (1990) Identification of an inhibitor of neovascularization from cartilage. Science 248, 1408-1410
5. Langer, R., and Moses, M. A. (1991) Angiogenesis inhibitors. Biotechnology 9, 630-634
6. Moses, M. A., Sudhalter, J., and Langer, R. (1992) Isolation and characterization of an inhibitor of neovascularization from scapular chondrocytes. J. Cell Biol. 119, 475-482
7. Hiraki, Y., Inoue, H., Iyama, K., Kamizono, A., Ochiai, M., Shukunami, C., Iijima, S., Suzuki, F., and Kondo, J. (1997) Identification of chondromodulin I as a novel endothelial cell growth inhibitor: purification and its localization in the avascular zone of epiphyseal cartilage. J. Biol. Chem. 272, 32419-32426
8. Kusafuka, K., Hiraki, Y., Shukunami, C., Kayano, T., and Takemura, T. (2002) Cartilage-specific matrix protein, chondromodulin-I (ChM-I), is a strong angio-inhibitor in endochondral ossification of human neonatal vertebral tissues in vivo: relationship with angiogenic factors in the cartilage. Acta Histochem. 104, 167-175
9. Shukunami, C., and Hiraki, Y. (2007) Chondromodulin-I and tenomodulin: the negative control of angiogenesis in connective tissue. Curr. Pharm. Des. 13, 2101-2112
10. Shukunami, C., Oshima, Y., and Hiraki, Y. (2001) Molecular cloning of tenomodulin, a novel chondromodulin-I related gene. Biochem. Biophys. Res. Commun. 280, 1323-1327
11. Oshima, Y., Sato, K., Tashiro, F., Miyazaki, J., Nishida, K., Hiraki, Y., Tano, Y., and Shukunami, C. (2004) Anti-angiogenic action of the C-terminal domain of tenomodulin that shares homology with chondromodulin-I. J. Cell Sci. 117, 2731-2744
12. Shukunami, C., Oshima, Y., and Hiraki, Y. (2005) Chondromodulin-I and tenomodulin: a new class of tissue-specific angiogenesis inhibitors found in hypovascular connective tissues. Biochem. Biophys. Res. Commun. 333,299-307
13. Moses, M. A., Wiederschain, D., Wu, I., Fernandez, C. A., Ghazizadeh, V., Lane, W. S., Flynn, E., Sytkowski, A., Tao, T., and Langer, R. (1999) Troponin I is present in human cartilage and inhibits angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 96, 2645-2650
14. Lee, A., and Langer, R. (1983) Shark cartilage contains inhibitors of tumor angiogenesis. Science 221, 1185-1187
15. Sheu, J. R., Fu, C. C., Tsai, M. L., and Chung, W. J. (1998) Effect of U-995, a potent shark cartilage-derived angiogenesis inhibitor, on anti-angiogenesis and anti-tumor activities. Anticancer Res. 18, 4435-4441
16. Shen, X. R., Ji, D. M., Hu, Y. Q., Jia, F. X., Wang, L., Chu, Z. Y., and Ren, D. M. (2001) SCAIF80, a novel inhibitor of angiogenesis, and its effect on tumor growth. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao 33, 99-104
17. Rabbani-Chadegani, A., Abdossamadi, S., Bargahi, A., and Yousef-Masboogh, M. (2008) Identification of low-molecular-weight protein (SCP1) from shark cartilage with anti-angiogenesis activity and sequence similarity to parvalbumin. J. Pharm. Biomed. Anal. 46, 563-567
18. Gingras, D., Renaud, A., Mousseau, N., Beaulieu, E., Kachra, Z., and Béliveau, R. (2001) Matrix proteinase inhibition by AE-941, a multifunctional antiangiogenic compound. Anticancer Res. 21, 145-155
19. Béliveau, R., Gingras, D., Kruger, E. A., Lamy, S., Sirois, P., Simard, B., Sirois, M. G., Tranqui, L., Baffert, F., Beaulieu, E., Dimitriadou, V., Pépin, M. C., Courjal, F., Ricard, I., Poyet, P., Falardeau, P., Figg, W. D., and Dupont, E. (2002) The antiangiogenic agent Neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects. Clin. Cancer Res. 8, 1242-1250
20. Dupont, E., Falardeau, P., Mousa, S. A., Dimitriadou, V., Pepin, M. C., Wang, T., and Alaoui-Jamali, M. A. (2002) Antiangiogenic and antimetastatic properties of Neovastat (AE-941), an orally active extract derived from cartilage tissue. Clin. Exp. Metastasis 19, 145-153
21. Kim, J. T., Kim, M. S., Bae, M. K., Song, H. S., Ahn, M. Y., Kim, Y. J., Lee, S. J., and Kim, K. W. (2001) Cloning and characterization of tissue inhibitor of metalloproteinase-3 (TIMP-3) from shark, Scyliorhinus torazame. Biochim. Biophys. Acta 1517, 311-315
22. Kang, J. A., Kim, J. T., Song, H. S., Bae, M. K., Yi, E. Y., Kim, K. W., and Kim, Y. J. (2003) Anti-angiogenic and anti-tumor invasive activities of tissue inhibitor of metalloproteinase-3 from shark, Scyliorhinus torazame. Biochim. Biophys. Acta 1620, 59-64
23. Paulsson, M., and Heinegård, D. (1982) Radioimmunoassay of the 148-kilodalton cartilage protein: distribution of the protein among bovine tissues. Biochem. J. 207, 207-213
24. Neame, P. J., Tapp, H., and Azizan, A. (1999) Noncollagenous, nonproteoglycan macromolecules of cartilage. Cell. Mol. Life Sci. 55, 1327-1340
25. Wiberg, C., Klatt, A. R., Wagener, R., Paulsson, M., Bateman, J. F., Heinegård, D., and Mörgelin, M. (2003) Complexes of matrilin-1 and biglycan or decorin connect collagen VI microfibrils to both collagen II and aggrecan. J. Biol. Chem. 278, 37698-37704
26. Winterbottom, N., Tondravi, M. M., Harrington, T. L., Klier, F. G., Vertel, B. M., and Goetinck, P. F. (1992) Cartilage matrix protein is a component of the collagen fibril of cartilage. Dev. Dyn. 193, 266-276
27. Mann, H. H., Ozbek, S., Engel, J., Paulsson, M., and Wagener, R. (2004) Interactions between the cartilage oligomeric matrix protein and matrilins: implications for matrix assembly and the pathogenesis of chondrodysplasias. J. Biol. Chem. 279, 25294-25298
28. Chen, Q., Zhang, Y., Johnson, D. M., and Goetinck, P. F. (1999) Assembly of a novel cartilage matrix protein filamentous network: molecular basis of differential requirement of von Willebrand factor A domains. Mol. Biol. Cell 10, 2149-2162
29. Roy, R., Louis, G., Loughlin, K. R., Wiederschain, D., Kilroy, S. M., Lamb, C. C., Zurakowski, D., and Moses, M. A. (2008) Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species. Clin. Cancer Res. 14, 6610-6617
30. MacCoss, M. J., Wu, C. C., and Yates, J. R., 3rd (2002) Probability-based validation of protein identifications using a modified SEQUEST algorithm. Anal. Chem. 74, 5593-5599
31. Zhang, Y., and Chen, Q. (2000) Changes of matrilin forms during endochondral ossification: molecular basis of oligomeric assembly. J. Biol. Chem. 275, 32628-32634
32. Fernández, C. A., Butterfield, C., Jackson, G., and Moses, M. A. (2003) Structural and functional uncoupling of the enzymatic and angiogenic inhibitory activities of tissue inhibitor of metalloproteinase-2 (TIMP-2): loop 6 is a novel angiogenesis inhibitor. J. Biol. Chem. 278, 40989-40995
33. Hiltunen, A., Vuorio, E., and Aro, H. T. (1993) A standardized experimental fracture in the mouse tibia. J. Orthop. Res. 11, 305-312
34. Zilberman, Y., Kallai, I., Gafni, Y., Pelled, G., Kossodo, S., Yared, W., and Gazit, D. (2008) Fluorescence molecular tomography enables in vivo visualization and quantification of nonunion fracture repair induced by genetically engineered mesenchymal stem cells. J. Orthop. Res. 26, 522-530
35. Chen, Q., Johnson, D. M., Haudenschild, D. R., and Goetinck, P. F. (1995) Progression and recapitulation of the chondrocyte differentiation program: cartilage matrix protein is a marker for cartilage maturation. Dev. Biol. 172, 293-306
36. Harper, J., and Moses, M. A. (2006) Molecular regulation of tumor angiogenesis: mechanisms and therapeutic implications. EXS 96, 223-268
37. de Lange Davies, C., Engesaeter, B. Ø., Haug, I., Ormberg, I. W., Halgunset, J., and Brekken, C. (2001) Uptake of IgG in osteosarcoma correlates inversely with interstitial fluid pressure, but not with interstitial constituents. Br. J. Cancer 85, 1968-1977
38. Grant, D. S., Yenisey, C., Rose, R. W., Tootell, M., Santra, M., and Iozzo, R. V. (2002) Decorin suppresses tumor cell-mediated angiogenesis. Oncogene 21, 4765-4777
39. Bornstein, P. (2009) Thrombospondins function as regulators of angiogenesis. J. Cell Commun. Signal. 3, 189-200
40. Good, D. J., Polverini, P. J., Rastinejad, F., Le Beau, M. M., Lemons, R. S., Frazier, W. A., and Bouck, N. P. (1990) A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl. Acad. Sci. U.S.A. 87, 6624-6628
41. Ren, B., Yee, K. O., Lawler, J., and Khosravi-Far, R. (2006) Regulation of tumor angiogenesis by thrombospondin-1. Biochim. Biophys. Acta 1765, 178-188
42. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., and Folkman, J. (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277-285
43. Wen, W., Moses, M. A., Wiederschain, D., Arbiser, J. L., and Folkman, J. (1999) The generation of endostatin is mediated by elastase. Cancer Res. 59, 6052-6056
44. Petitclerc, E., Boutaud, A., Prestayko, A., Xu, J., Sado, Y., Ninomiya, Y., Sarras, M. P., Jr., Hudson, B. G., and Brooks, P. C. (2000) New functions for non-collagenous domains of human collagen type IV: novel integrin ligands inhibiting angiogenesis and tumor growth in vivo. J. Biol. Chem. 275, 8051-8061
45. Maeshima, Y., Colorado, P. C., Torre, A., Holthaus, K. A., Grunkemeyer, J. A., Ericksen, M. B., Hopfer, H., Xiao, Y., Stillman, I. E., and Kalluri, R. (2000) Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J. Biol. Chem. 275, 21340-21348
46. Nyberg, P., Xie, L., Sugimoto, H., Colorado, P., Sund, M., Holthaus, K., Sudhakar, A., Salo, T., and Kalluri, R. (2008) Characterization of the antiangiogenic properties of arresten, an α1ß1 integrin-dependent collagenderived tumor suppressor. Exp. Cell Res. 314, 3292-3305
47. Kamphaus, G. D., Colorado, P. C., Panka, D. J., Hopfer, H., Ramchandran, R., Torre, A., Maeshima, Y., Mier, J. W., Sukhatme, V. P., and Kalluri, R. (2000) Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J. Biol. Chem. 275, 1209-1215
48. Sottile, J. (2004) Regulation of angiogenesis by extracellular matrix. Biochim. Biophys. Acta 1654, 13-22
49. Sund, M., Nyberg, P., and Eikesdal, H. P. (2010) Endogenous matrix-derived inhibitors of angiogenesis. Pharmaceuticals 3, 3021-3039
50. Luo, H., Xu, J., and Yu, X. (2007) Isolation and bioactivity of an angiogenesis inhibitor extracted from the cartilage of Dasyatis akajei. Asia Pac. J. Clin. Nutr. 16, 286-289
51. Falardeau, P., Champagne, P., Poyet, P., Hariton, C., and Dupont, E. (2001) Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin. Oncol. 28, 620-625
52. Batist, G., Patenaude, F., Champagne, P., Croteau, D., Levinton, C., Hariton, C., Escudier, B., and Dupont, E. (2002) Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels. Ann. Oncol. 13, 1259-1263
53. Latreille, J., Batist, G., Laberge, F., Champagne, P., Croteau, D., Falardeau, P., Levinton, C., Hariton, C., Evans, W. K., and Dupont, E. (2003) Phase I/II trial of the safety and efficacy of AE-941 (Neovastat) in the treatment of non-small-cell lung cancer. Clin. Lung Cancer 4, 231-236
54. Sauder, D. N., Dekoven, J., Champagne, P., Croteau, D., and Dupont, E. (2002) Neovastat (AE-941), an inhibitor of angiogenesis: randomized phase I/II clinical trial results in patients with plaque psoriasis. J. Am. Acad. Dermatol. 47, 535-541
55. Lu, C., Lee, J. J., Komaki, R., Herbst, R. S., Feng, L., Evans, W. K., Choy, H., Desjardins, P., Esparaz, B. T., Truong, M. T., Saxman, S., Kelaghan, J., Bleyer, A., and Fisch, M. J. (2010) Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial. J. Natl. Cancer Inst. 102, 859-865
56. Escudier, B., Choueiri, T. K., Oudard, S., Szczylik, C., Négrier, S., Ravaud, A., Chevreau, C., Venner, P., Champagne, P., Croteau, D., Dupont, E., Hariton, C., and Bukowski, R. M. (2007) Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE-941. J. Urol. 178, 1901-1905